Showing 4051-4060 of 8199 results for "".
- Pediatric Atopic Dermatitis Associated with Learning, Memory Difficultieshttps://practicaldermatology.com/news/symptoms-of-cognitive-impairment-among-children-with-atopic-dermatitis/2462263/New research links pediatric atopic dermatitis (AD) with higher odds of memory and learning difficulties. "Previous studies suggest that atopic dermatitis (AD) is associated with cognitive impairment in children, but these studie
- Report: Unacceptably High Benzene Levels Detected in Numerous Acne Products Containing BPOhttps://practicaldermatology.com/news/report-unacceptably-high-benzene-levels-detected-in-numerous-acne-products-containing-bpo/2462262/An independent laboratory has reported that it has detected elevated levels of benzene in a number of widely used acne products, according to a press release. Valisure, an independent testing laboratory based in Connecticut, has filed a
- After Positive Phase 1 Results, Apogee to Test Twice-Yearly Dosing of Atopic Dermatitis Drug Candidatehttps://practicaldermatology.com/news/after-positive-phase-1-results-apogee-to-test-twice-yearly-dosing-of-atopic-dermatitis-drug-candidate/2462261/Apogee Therapeutics announced positive interim phase 1 data from its first-in-human study of APG777, one of its lead product candidates being developed as a frontline treatment for moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases. Pharmacokinetic (PK) data showed a half-l
- Bimekizumab Not Linked with Depression, Suicidal Ideation in Moderate-to-Severe Psoriasishttps://practicaldermatology.com/news/mental-health-outcomes-in-patients-with-moderate-to-severe-psoriasis-treated-with-bimekizumab-analysis-of-phase-23-randomized-trials/2462260/A new analysis indicates that bimekizumab was not associated with a high risk of suicidal ideation/behavior (SIB) and depression. Psoriasis patients often face increased risks of SIB and depression, according to the researchers. Bimekizumab, an FDA-approved biologic inhibiting
- Galderma to Showcase Latest Updates From Its Dermatology Portfolio at the 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/galderma-to-showcase-latest-updates-from-its-dermatology-portfolio-at-the-2024-american-academy-of-dermatology-annual-meeting-1/2462259/Galderma will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) annual meeting from March 8-12, 2024, highlighting its dermatology portfolio. Galderma’s presence includes two late-breaking presentations on its first-in-class, investi
- Dermavant to Present New ADORING Data from Phase 3 Trials of Vtama Cream for AD at 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/dermavant-to-present-new-adoring-data-from-phase-3-trials-of-vtama-cream-for-ad-at-2024-aad-annual-meeting/2462258/Dermavant Sciences announced that new ADORING data, including treatment of patients with skin of color, from phase 3 trials of Vtama (tapinarof) cream 1% in adults and children 2 years of age and older with atopic dermatitis (AD), will be presented at the 2024 American Academy of Dermatology annu
- 595-nm Pulsed Dye Laser with 1565-nm Nonablative Fractional Laser Safe, Effective for Acnehttps://practicaldermatology.com/news/treatment-of-erythematous-acne-scars-using-595-nm-pulsed-dye-laser-combined-with-1565-nm-resurfx-nonablative-fractional-laser/2462257/The use of a 595-nm pulsed dye laser (PDL) and 1565-nm nonablative fractional laser (NAFL) was seen as safe and efficacious in patients with acne vulgarism, according to a new study in the Journal of Cosmetic Dermatology. "Acne erythema has been considered simple ery
- Long-term Outcomes Impaired by Cutaneous Chronic Graft-vs-Host Diseasehttps://practicaldermatology.com/news/improved-melanoma-prognosis-with-31-gep/2462255/New analysis results indicate that cutaneous chronic graft-vs-host disease (GVHD) was linked with impaired long-term patient-reported outcomes (PROs). Researchers for the 9-center study conducted by the Chronic GVHD Consortium examined the association between different ty
- La Roche-Posay Launches New Dark Spot Serumhttps://practicaldermatology.com/news/la-roche-posay-launches-dark-spot-serum/2462254/La Roche-Posay, a subsidiary of L'oreal, recently announced the launch of its new a new serum corrector for dark spots, the Mela B3 Dark Spot Serum with MelasylTM + Nicinamide. According to the manufacturer, the launch was preceded by 18 years of research, as well as rese
- Nutrafol® Announces Expansion Into Skin with Daily Acne Supplementhttps://practicaldermatology.com/news/hair-health-leader-nutrafol-expands-into-skin/2462253/Hair health leader Nutrafol has announced an expansion into the skin space with the launch of its new product, Nutrafol Skin. According to the manufacturer, the first-of-its-kind once-daily supplement for women 18 years of age and older who experience mild to moderate acne. A